Your browser doesn't support javascript.
loading
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis.
Barriga, Francisco M; Tsanov, Kaloyan M; Ho, Yu-Jui; Sohail, Noor; Zhang, Amy; Baslan, Timour; Wuest, Alexandra N; Del Priore, Isabella; Meskauskaite, Brigita; Livshits, Geulah; Alonso-Curbelo, Direna; Simon, Janelle; Chaves-Perez, Almudena; Bar-Sagi, Dafna; Iacobuzio-Donahue, Christine A; Notta, Faiyaz; Chaligne, Ronan; Sharma, Roshan; Pe'er, Dana; Lowe, Scott W.
Afiliación
  • Barriga FM; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tsanov KM; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ho YJ; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sohail N; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang A; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Baslan T; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wuest AN; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Del Priore I; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, New York, NY, USA.
  • Meskauskaite B; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Livshits G; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alonso-Curbelo D; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Simon J; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chaves-Perez A; Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bar-Sagi D; Department of Biochemistry, New York University School of Medicine, New York, NY, USA.
  • Iacobuzio-Donahue CA; David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Notta F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chaligne R; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Sharma R; Division of Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Pe'er D; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Lowe SW; Program for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Cancer ; 3(11): 1367-1385, 2022 11.
Article en En | MEDLINE | ID: mdl-36344707
ABSTRACT
The most prominent homozygous deletions in cancer affect chromosome 9p21.3 and eliminate CDKN2A/B tumor suppressors, disabling a cell-intrinsic barrier to tumorigenesis. Half of 9p21.3 deletions, however, also encompass a type I interferon (IFN) gene cluster; the consequences of this co-deletion remain unexplored. To functionally dissect 9p21.3 and other large genomic deletions, we developed a flexible deletion engineering strategy, MACHETE (molecular alteration of chromosomes with engineered tandem elements). Applying MACHETE to a syngeneic mouse model of pancreatic cancer, we found that co-deletion of the IFN cluster promoted immune evasion, metastasis and immunotherapy resistance. Mechanistically, IFN co-deletion disrupted type I IFN signaling in the tumor microenvironment, leading to marked changes in infiltrating immune cells and escape from CD8+ T-cell surveillance, effects largely driven by the poorly understood interferon epsilon. These results reveal a chromosomal deletion that disables both cell-intrinsic and cell-extrinsic tumor suppression and provide a framework for interrogating large deletions in cancer and beyond.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Interferones / Neoplasias Límite: Animals Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Interferones / Neoplasias Límite: Animals Idioma: En Revista: Nat Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos